Alectinib is a second-generation oral kinase inhibitor indicated for the treatment of ALK-positive metastatic non-small cell lung cancer, functioning by selectively blocking the activity of the anaplastic… Read more














![Chemical structure of N-(1-((3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)(nitroso)amino)pentan-3-yl)-N-(2-ethoxyethyl)nitrous amide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-1-3-Cyano-9-ethyl-66-dimethyl-11-oxo-611-dihydro-5H-benzobcarbazol-8-ylnitrosoaminopentan-3-yl-N-2-ethoxyethylnitrous-amide.png&w=3840&q=75)
![Chemical structure of N-(1-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)piperidin-4-yl)-N-(2-ethoxyethyl)nitrous amide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-1-3-Cyano-9-ethyl-66-dimethyl-11-oxo-611-dihydro-5H-benzobcarbazol-8-ylpiperidin-4-yl-N-2-ethoxyethylnitrous-amide.png&w=3840&q=75)
![Chemical structure of N-(3-Cyano-9-ethyl-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazol-8-yl)-N-(3-morpholinopentyl)nitrous amide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-3-Cyano-9-ethyl-66-dimethyl-11-oxo-611-dihydro-5H-benzobcarbazol-8-yl-N-3-morpholinopentylnitrous-amide.png&w=3840&q=75)










Alectinib is a second-generation oral kinase inhibitor indicated for the treatment of ALK-positive metastatic non-small cell lung cancer, functioning by selectively blocking the activity of the anaplastic lymphoma kinase (ALK) receptor to inhibit tumor growth. This category provides a comprehensive collection of Alectinib reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories engaged in rigorous analytical testing, method validation, and quality control. By utilizing these precisely characterized reference standards, researchers can perform accurate impurity profiling and quantitative bioanalysis, such as LC-MS/MS studies, to ensure the safety, identity, and potency of the drug product. The availability of stable isotope-labelled forms further facilitates precise measurement by compensating for matrix effects during complex sample analysis. Collectively, these tools support the development, manufacturing, and regulatory compliance of Alectinib-based therapies throughout the pharmaceutical product lifecycle.